Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective
ResMed Analyst Ratings
Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280
Needham Maintains ResMed(RMD.US) With Hold Rating
Resmed (RMD) Receives a Hold From Needham
ResMed Analyst Ratings
Wolfe Research Downgrades ResMed(RMD.US) to Sell Rating, Announces Target Price $180
Wolfe Research Downgrades ResMed to Underperform From Peer Perform, Price Target Is $180
ResMed Faces Market Disruption and Limited Growth: A Sell Rating Analysis
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
ResMed Price Target Maintained With a $236.00/Share by Needham
Needham Downgrades ResMed(RMD.US) to Hold Rating
Resmed (RMD) Was Downgraded to a Hold Rating at Needham
William Blair Initiates ResMed(RMD.US) With Buy Rating
Morgans Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $206